<DOC>
	<DOCNO>NCT02430532</DOCNO>
	<brief_summary>The primary objective study investigate whether treatment BG00012 ( dimethyl fumarate ) compare placebo slow accumulation disability relate relapse participant secondary progressive multiple sclerosis ( SPMS ) . The secondary objective study assess effect BG00012 compare placebo patient-reported outcome , brain atrophy , cognitive function .</brief_summary>
	<brief_title>BG00012 Delay Disability Progression Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Onset SPMS least 1 2 year prior randomization . SPMS define relapsingremitting disease follow progression disability independent explain relapse . Have document confirm evidence disease progression independent clinical relapse 1 year prior randomization . Have Expanded Disability Status Scale score 3.0 6.5 , inclusive . Have Multiple Sclerosis ( MS ) Severity Score 4 high . Key Have diagnosis relapse remit multiple sclerosis primary progressive MS define revise McDonald criterion . Had recent clinical relapse ( within 3 month ) prior randomization . Uncontrolled intercurrent illness include , limited : ongoing active infection ; symptomatic congestive heart failure ; unstable angina pectoris ; cardiac arrhythmia ; serious acute liver , kidney , bone marrow dysfunction ; uncontrolled diabetes ; serious acute psychiatric illness would limit compliance study requirement . Note : Other protocoldefined Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>INSPIRE</keyword>
	<keyword>SPMS</keyword>
	<keyword>Tecfidera</keyword>
	<keyword>BG00012</keyword>
</DOC>